-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the research team of China Thymic Oncology Collaborative Group (ChART) led by Professor Fang Wentao, director of the Department of Thoracic Surgery of Shanghai Chest Hospital, published the latest research in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (ISLAC) and an international authoritative academic journal in the field of thoracic oncology.
Lung Cancer Management
The Chinese Alliance for Thymoma Research (ChART) retrospective database contains data on patients treated with TET at 18 tertiary referral centers in the People's Republic of China from 1994 to 2012
The Chinese Alliance for Thymoma Research (ChART) retrospective database contains data on patients treated with TET at 18 tertiary referral centers in the People's Republic of China from 1994 to 2012
907 IASLC/ITMIG stage I to IIIa TET patients who underwent R0 resection between 1994 and 2012 were identified from the ChART database
With a median follow-up of 52 months (range, 4-147 months), the 10-year OS rate for all patients was 89.
Table 2 shows the results of univariate analysis of recurrence-free survival
Table 2 shows the results of univariate analysis of recurrence-free survival
In multivariate analysis, only increased WHO histology (NETT vs thymic carcinoma vs B2 and B3 thymoma vs A, AB and B1 thymoma [p < 0.
For the 53 patients who relapsed during follow-up, the median time to relapse was 23 months (range 1-108 months)
For the 53 patients who relapsed during follow-up, the median time to relapse was 23 months (range 1-108 months)
Shanghai Chest Hospital has accumulated rich experience and achievements in the clinical diagnosis, treatment and research of mediastinal diseases, especially thymic tumors
This study established the world's first postoperative recurrence prediction model for thymic tumors, and provided corresponding long-term follow-up recommendations for patients with different recurrence risks, which not only helps in timely detection and treatment, but also reduces unnecessary examinations, allowing patients to Get a safer and better postoperative quality of life
Quality of life diagnosis and treatment guidelines
Original source:
Liu H, Gu Z, Qiu B, Detterbeck FC, Roden AC, Ruffini E, Okumura M, Girard N, Xiang Y, Liu Y, Du Z, Hao Y, Fu J, Zhang P, Pang L, Chen K, Wang Y , Yu Z, Mao T, Fang W; AME Thoracic Surgery Cooperative Group.
A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study.
Leave a comment here